Clinical Trial Update: Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing the pembrolizumab/vibostolimab coformulation MK-7684A with pembrolizumab monotherapy in PD-L1–positive metastatic non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• Vibostolimab (vibostolimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lung Neoplasms, Non-Small-Cell Lung Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2025-08-26